Hodgkin lymphoma

Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer

Retrieved on: 
星期一, 八月 10, 2020
Immunology, Clinical medicine, Hodgkin lymphoma, RTT, CD37, Antibody, Branches of biology, Medicine

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.
  • Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer

Retrieved on: 
星期一, 八月 10, 2020
Immunology, Clinical medicine, Hodgkin lymphoma, RTT, CD37, Antibody, Branches of biology, Medicine

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.
  • Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
星期四, 八月 6, 2020
Medical specialties, Clinical medicine, RTT, Cancer, T cells, CD30, Chimeric antigen receptor T cell, Lymphoma, Hodgkin lymphoma, Brentuximab vedotin, Enteropathy-associated T-cell lymphoma

Results of the trials, which evaluated the safety and efficacy of CD30 CAR-T cell therapy in patients with relapsed/refractory ("R/R") Hodgkin lymphoma, showed a high rate of durable complete responses and very favorable safety profile using autologous CD30 CAR-T cell therapy.

Key Points: 
  • Results of the trials, which evaluated the safety and efficacy of CD30 CAR-T cell therapy in patients with relapsed/refractory ("R/R") Hodgkin lymphoma, showed a high rate of durable complete responses and very favorable safety profile using autologous CD30 CAR-T cell therapy.
  • The trials enrolled 41 adult patients with relapsed/refractory Hodgkin Lymphoma who received CD30 CAR-T cell therapy following lymphodepletion with chemotherapy.
  • Tessa's clinical pipeline derives from two innovative cell therapy platforms: CD30 Chimeric Antigen Receptors (CD30-CARs) and Virus-Specific T cells (VSTs).
  • Our lead candidate comprises autologous CD30 CAR-T cell therapy targeting classical Hodgkin lymphoma (cHL) and CD30+ non-Hodgkin lymphomas.

Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
星期四, 八月 6, 2020
Medical specialties, Clinical medicine, RTT, Cancer, T cells, CD30, Chimeric antigen receptor T cell, Lymphoma, Hodgkin lymphoma, Brentuximab vedotin, Enteropathy-associated T-cell lymphoma

Results of the trials, which evaluated the safety and efficacy of CD30 CAR-T cell therapy in patients with relapsed/refractory ("R/R") Hodgkin lymphoma, showed a high rate of durable complete responses and very favorable safety profile using autologous CD30 CAR-T cell therapy.

Key Points: 
  • Results of the trials, which evaluated the safety and efficacy of CD30 CAR-T cell therapy in patients with relapsed/refractory ("R/R") Hodgkin lymphoma, showed a high rate of durable complete responses and very favorable safety profile using autologous CD30 CAR-T cell therapy.
  • The trials enrolled 41 adult patients with relapsed/refractory Hodgkin Lymphoma who received CD30 CAR-T cell therapy following lymphodepletion with chemotherapy.
  • Tessa's clinical pipeline derives from two innovative cell therapy platforms: CD30 Chimeric Antigen Receptors (CD30-CARs) and Virus-Specific T cells (VSTs).
  • Our lead candidate comprises autologous CD30 CAR-T cell therapy targeting classical Hodgkin lymphoma (cHL) and CD30+ non-Hodgkin lymphomas.